Smith, Michael A.
Henault, Jill
Karnell, Jodi L.
Parker, Melissa L.
Riggs, Jeffrey M.
Sinibaldi, Dominic
Taylor, Devon K.
Ettinger, Rachel
Grant, Ethan P.
Sanjuan, Miguel A.
Kolbeck, Roland
Petri, Michelle A.
Casey, Kerry A. http://orcid.org/0000-0001-7194-8585
Article History
Received: 12 March 2019
Accepted: 27 August 2019
First Online: 8 October 2019
Competing Interests
: J.M.R., D.S., D.K.T. and R.K. are employees of AstraZeneca and hold stock and/or stock options in AstraZeneca. M.A.Sm., J.L.K. and R.E. were employees of AstraZeneca at the time that this analysis was conducted and are now employees of Viela Bio; they hold stock and/or stock options in AstraZeneca and are shareholders at Viela Bio. J.H. was an employee of AstraZeneca at the time that this analysis was conducted and is now an employee of Celgene. M.L.P. was an employee of AstraZeneca at the time that this analysis was conducted and is now an employee of Incyte. E.P.G. was an employee of AstraZeneca at the time that this analysis was conducted and is now an employee of Gilead. M.A.Sa. was an employee of AstraZeneca at the time that this analysis was conducted and is now an employee of Bristol-Myers Squibb. M.A.P. was formerly a consultant for AstraZeneca. K.A.C. was an employee of AstraZeneca at the time that this analysis was conducted and is now an employee of the Allen Institute for Immunology.